Publications by authors named "M L Grove"
Background/objectives: Cirrhosis is the precursor to most cases of hepatocellular carcinoma (HCC). Understanding the mechanisms leading to the transition from cirrhosis to HCC and identifying key biomarkers is crucial to developing effective screening strategies and reducing HCC-related mortality. DNA methylation is associated with gene inactivation and plays an important role in physiological and pathological processes; however, its role in cirrhosis progression to HCC is unknown.
View Article and Find Full Text PDFThe relationship between mitochondrial DNA (mtDNA) heteroplasmy and nuclear DNA (nDNA) methylation (CpGs) remains to be studied. We conducted an epigenome-wide association analysis of heteroplasmy burden scores across 10,986 participants (mean age 77, 63% women, and 54% non-White races/ethnicities) from seven population-based observational cohorts. We identified 412 CpGs (FDR p < 0.
View Article and Find Full Text PDFArticle Synopsis
- * The study shows that heteroplasmy is more prevalent in people with clonal hematopoiesis, especially when there are multiple mutations or certain types of mutations present.
- * Including heteroplasmy in risk assessment models enhances the ability to identify high-risk individuals for myeloid neoplasms, indicating its potential as a significant biomarker for these conditions.
Article Synopsis
- Circulating metabolite levels are indicators of human health and can be influenced by genetic factors; however, most research has focused on European populations.
- The study utilized metabolomics data from 25,058 diverse individuals, identifying 1,778 gene loci linked to 667 metabolites and providing methods for data analysis and handling.
- Notably, the research uncovered new genetic associations, including 108 novel gene-metabolite pairs, and highlighted sex differences in metabolism, enhancing the understanding of genetic influences on human health.
Article Synopsis
- Neurofibromatosis type 2 (NF2) is a rare condition leading to tumors like vestibular schwannomas and meningiomas, and currently lacks FDA approved medication.* -
- Previous research shows that BET inhibition can slow the growth of NF2-related cells, and this study investigates whether combining both BET and FAK inhibition could enhance these effects.* -
- Results indicate that this combination effectively halts the growth of NF2-null cells by disrupting their cell cycle and significantly downregulating FAK1, suggesting a promising new treatment approach for NF2-related tumors.*